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Abstract. In less than 10 years, melanoma treatment has been 
revolutionized with the approval of tyrosine kinase inhibitors 
and immune checkpoint inhibitors, which have been shown 
to have a significant impact on the prognosis of patients with 
melanoma. The early steps of this transformation have taken 
place in research laboratories. The mitogen-activated protein 
kinase (MAPK) pathway, phosphoinositol-3-kinase (PI3K) 
pathway promote the development of melanoma through 
numerous genomic alterations on different components of these 
pathways. Moreover, melanoma cells deeply interact with the 
tumor microenvironment and the immune system. This knowl-
edge has led to the identification of novel therapeutic targets and 
treatment strategies. In this review, the epidemiological features 
of cutaneous melanoma along with the biological mechanisms 
involved in its development and progression are summarized. 
The current state-of-the-art of advanced stage melanoma treat-
ment strategies and the currently available evidence of the use of 
predictive and prognostic biomarkers are also discussed.
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1. Epidemiology and risk factors
The worldwide incidence of cutaneous melanoma has been 
increasing annually at a more rapid rate compared to any other 
type of cancer (1). In 2012, 232,000 new cases of melanoma 
and 55,000 deaths were registered worldwide, ranking 15th 
among most common cancers worldwide (2). The incidence of 
cutaneous melanoma varies greatly between countries and these 
different incidence patterns are ascribed to variations in racial 
skin phenotype, as well as differences in sun exposure. Moreover, 
unlike other solid tumors, melanoma mostly affects young and 
middle-aged individuals (median age at diagnosis, 57 years). 
The incidence increases linearly after the age of 25 years until 
the age of 50 years, and then decreases, particularly in the 
female sex. When analyzing incidence data in relation to sex, 
women are more frequent in younger aged groups, while the 
male sex prevails from the age of 55 onwards (3).
Ultraviolet (UV) light radiation from sunlight is the main 
environmental risk factor for melanoma skin cancer develop-
ment (4-6). The increased risk of melanoma due to sun exposure 
is directly associated with the UV level and in particular to 
the UV-B spectrum (5). In addition, sun exposure patterns and 
timing have been associated in a number of studies with an 
increased risk of melanoma. In particular, intense and inter-
mittent sun exposure (typical of sunburn history) is associated 
with a higher risk compared to a chronic continuous pattern of 
sun exposure that is more frequently associated with actinic 
keratosis and non-melanoma skin cancers (7-10). Furthermore, 
a history of sunburn in childhood or adolescence is associated 
with the highest risk of developing melanoma and individuals 
experiencing >5 episodes of severe sunburn have a 2-fold 
increased risk (8,11). UV‑A exposure from artificial sources 
has been also linked to an increased risk of developing mela-
noma. The follow-up of patients with psoriasis receiving UV-A 
radiation phototherapy, as well as in individuals using sunbeds 
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has revealed an increased risk of melanoma in this popula-
tion (12,13). Specifically, several studies and a meta‑analysis 
have demonstrated a positive association between the risk of 
developing melanoma and the amount of sunbed usage, partic-
ularly from a young age, thus raising a major public health 
issue (12,14,15). UV light from sunbeds has been formally 
classified as a human carcinogen (14). No other environmental 
factors, including tobacco/smoke addiction, have been associ-
ated with melanoma (1).
In addition, host risks factors, such as the number of congen-
ital and acquired melanocytic nevi, genetic susceptibility and a 
family history play a central role in the development of mela-
noma (16-18). Approximately 25% of melanoma cases arise 
on a pre-existing nevus (19). In this context, not only the total 
number of nevi, but also the size and type of nevi, are individu-
ally associated with an increased risk of melanoma (20-23).
As regards genetic susceptibility, the polymorphisms of the 
melanocortin 1 receptor (MC1R) gene, are responsible for the 
different human skin-color phenotypes. Individuals with char-
acteristics, such as red hair, a light complexion and light eyes 
exhibit a low pigmentation, with a consequent heightened sensi-
tivity to UV exposure (24). Approximately 7-15% of melanoma 
cases occur in patients with a family history of melanoma (25). 
However, true hereditary melanoma (i.e., multi-generational, 
unilateral lineage, multiple primary lesions and early onset of 
the disease) are infrequent; the familial clustering of the disease 
is considered to be responsible for the presence of a transmitted 
genetic mutation (25,26). Over the past years, melanomas have 
also been found to arise in families that are generally prone to 
specific patterns of malignancies, such as the familial atypical 
multiple mole-melanoma syndrome (FAMMM syndrome) 
and its variant, the melanoma-astrocytoma syndrome 
(MAS) (26). Germline mutations in cyclin-dependent kinase 
inhibitor 2A (CDKN2A or p16) and, less common, mutations 
in cyclin-dependent kinase 4 (CDK4) are the most frequent 
genetic abnormalities identified in these families (26-28). 
Other inherited conditions associated with an increased risk of 
developing melanoma are xeroderma pigmentosum, familial 
retinoblastoma, Lynch syndrome type II and Li-Fraumeni 
cancer syndrome (25).
2. The genesis of malignant melanoma
Melanocytes are neural crest-derived cells that can be found 
principally in the basal epidermis and in hair follicles, along 
mucosal surfaces, meninges and in the choroidal layer of the 
eye (29). In response to UV-induced DNA damage, skin kerati-
nocytes produce the melanocyte stimulating hormone (MSH) 
that binds the melanocortin receptor 1 (MC1R) on the mela-
nocytes that than produce and release melanin. The melanin 
pigment ultimately operates as a shield for UV radiation, thus 
preventing further DNA alteration (30).
Cutaneous melanoma can be generally classified in the 
Caucasian population by its origin from chronically or inter-
mittent sun-exposed skin that translate into different sites of 
origin, a degree of cumulative UV exposure, age at diagnosis, 
types of oncogenic drivers and mutational load (9). Indeed, 
melanomas in chronically sun-exposed skin usually appear in 
older-aged individuals (>55 years), on chronically sun-exposed 
areas, such as the head and neck, as well as the dorsal region 
of the upper extremities. The main genetic drivers are B-Raf 
proto-oncogene (BRAF), neurofibromin 1 (NF1) and NRAS 
mutations, and usually melanomas associated with chronically 
sun-exposed skin have a high mutational load related to UV 
exposure (9,31,32). On the other hand, melanoma associated 
with intermittent sun-exposed skin cases arise in younger-aged 
individuals (<55 years), on less sun-exposed areas, such as the 
trunk and proximal extremities, and are usually associated 
with BRAFV600E and a lower mutational load (31,32).
Over the past years, a deeper understanding of melanoma 
development and biology has been reached. It has become 
clear that the development of fully-evolved melanoma from 
pre-neoplastic lesions is not represented by a single evolu-
tionary pattern. Each melanoma subtype can evolve from 
different precursor lesions, and can involve different gene 
mutations and stage of transformation (33). An interesting 
finding is that BRAF is mutated in up to 80% of benign 
nevi, resulting in limited melanocyte proliferation through 
the oncogene-mediated activation of cell senescence (34,35). 
These nevi remain indolent for decades also due to immune 
surveillance (36). Therefore, oncogenic BRAF alone is not 
sufficient for melanoma development and rarely benign nevi 
further progress to melanoma (33,37). When this usually 
occurs, it is associated with the acquisition of subsequent 
mutations in key genes, such as TERT or CDKN2A. On the 
other hand, melanomas associated with chronic sun-exposed 
skin usually do not arise form pre-existing nevi, but from 
melanomas in situ or dysplastic lesions and carry a different set 
of mutations (33). Histological characterization is the current 
mainstay of melanocytic neoplasia diagnosis and the defini-
tion of their malignant potential. However, histopathology is 
sometimes associated with the equivocal characterization of 
these lesions, leading to their improper risk stratification (38). 
The increasing understanding of the biological determinants 
of melanoma evolution and their potential integration in the 
management of melanoma patients may lead to an improve 
diagnosis and the earlier recognition of lesions at an increased 
risk of progression, thus improving patient risk stratifica-
tion (Fig. 1).
3. Melanoma biology
Cutaneous melanoma is one of the most aggressive forms of 
skin cancer and one of the leading causes of cancer-related 
mortality due its metastatic power. Several studies have 
demonstrated that melanoma spreading is the result of genetic 
mutations and tumor microenvironmental alterations, charac-
terized by the overexpression of proteins able to favor tumor 
invasion and surrounding infiltration (39‑44). In particular, 
a key role is played by the overexpression of matrix metal-
loproteinases (MMPs), particularly MMP-9 and MMP-2, that 
induces the degradation of the components of the extracellular 
matrix, thus favoring tumor cell infiltration and spreading 
through the bloodstream (40-42). The overexpression of these 
proteins and tumor microenvironmental alterations are medi-
ated by genetic alterations and the dysregulation of the nuclear 
factor (NF)-κB pathways. It has been demonstrated that 
MMP-9 overexpression observed in melanoma is caused by 
intragenic methylation phenomena that lead to protein overex-
pression (42). Furthermore, it has also been demonstrated that 
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NF-κB induces the overexpression of MMP-9 by the activation 
of osteopontin (OPN), another protein of the tumor microenvi-
ronment, thus playing a fundamental role in the development 
and progression of melanoma (43,44).
Apart from tumor microenvironmental alterations, mela-
nomas are associated with one of the greatest burdens of 
somatic genetic alterations of all human tumors (45,46). The 
most frequent somatic mutations in chronically or intermittent 
sun-exposed skin melanomas affect genes that control central 
cellular process, such us proliferation (BRAF, NRAS and NF1), 
growth and metabolism [phosphatase and tensin homolog 
(PTEN) and KIT proto-oncogene receptor tyrosine kinase 
(KIT)], resistance to apoptosis [tumor protein p53 (TP53)], 
cell cycle control [cyclin-dependent kinase inhibitor 2A 
(CDKN2A)] and replicative lifespan [telomerase reverse tran-
scriptase (TERT)] (47,48). These genomic alterations typically 
lead to the aberrant activation of two main signaling pathways 
in melanoma: The RAS/RAF/MEK/ERK signaling cascade 
[also known as the mitogen-activated protein kinase (MAPK) 
pathway] and the phosphoinositol-3-kinase (PI3K)/AKT 
pathway (49).
The MAPK pathway is physiologically involved in the 
transduction of extracellular signals, such as growth factors 
and hormones, to the nucleus, leading to the expression of 
genes that are central drivers of cell proliferation, differentia-
tion and survival (50,51). In addition, it has been shown that 
MAPK activation is a critical player in the biology of different 
types of cancer and is the most frequent pathway aberrantly 
activated in melanoma (52). The PI3K pathway is normally 
involved in cellular homeostasis and its activation has been 
demonstrated to be central in different cancer types, including 
melanoma where it is the second most frequently activated 
pathway (53,54).
Up to 90% of melanomas exhibit an aberrant MAPK 
pathway activation and this is a central step in melanoma 
development, being responsible for cell cycle deregulation 
and apoptosis inhibition (50,55,56). Among the different 
mechanisms responsible for abnormal MAPK pathway 
signaling in melanoma, the most frequent genetic abnormali-
ties are, by far, BRAF mutations (37,47). Indeed, 37 to 50% of 
melanomas carry a somatic mutation in the BRAF gene with 
the highest frequency in cutaneous melanomas derived from 
intermittent sun exposure damage (approximately 60% carry 
a BRAF mutation) (31). Usually, BRAF mutations detected in 
cutaneous melanoma are missense mutations that determine 
amino acid substitution at valine 600. Approximately 80-90% 
of BRAF mutations are V600E (valine to glutamic acid), 
while 5-12% are valine to lysine substitution (V600K) and 
≤5% are V600D (valine to aspartic acid) or V600R (valine to 
arginine) (57,58).
BRAF protein is a serine/threonine protein kinase of 
766 amino acids organized in three domains: Two with regu-
latory function and one catalytic domain responsible for MEK 
phosphorylation (59). The catalytic domain is also respon-
sible for maintaining the protein in its inactive conformation, 
through a hydrophobic interaction between the ‘so-called’ 
glycine-rich loop and the activation segment, making it 
inaccessible for ATP binding (59). In the BRAFV600E muta-
tion, hydrophobic valine is replaced by polar, hydrophilic 
glutamic acid, resulting in an abnormal flip of the catalytic 
domain that generates a constitutive active conformation 
with a kinase activity 500-fold higher than wild-type BRAF 
kinase (60,61). Most of the non-V600E BRAF mutations 
act similarly through the alteration of glycine-rich loop and 
activation segment interaction, thus increasing BRAF kinase 
activity (61).
The second most common cause of aberrant signaling 
through the MAPK pathway in cutaneous melanoma is repre-
sented by NRAS activating mutations. NRAS is mutated in 
15-30% of melanomas and in the majority of cases, these muta-
tions are missense mutations of codon 12, 13 or 61 (the latter 
account for 80% of all NRAS mutations in melanoma) (31,62). 
Mutations of these codons lead to the prolongation of the 
NRAS-active GTP-bound state, thus abnormally maintaining 
NRAS signaling through both the MAPK and the PI3K 
pathways (47,63,64). Importantly, NRAS and BRAF mutations 
are considered mutually exclusive; however, co-mutations 
can rarely occur (approximately 0.5% in treatment-naïve 
patients) (64).
NF1 is a tumor suppressor gene mutated in 10-15% of 
melanoma cases and is the third most frequently mutated 
gene in melanoma (65,66). The NF1 protein regulates 
the RAS family by converting the active RAS-guanosine 
triphosphate (RAS-GTP) to the inactive RAS-guanosine 
diphosphate (RAS-GDP), thereby inhibiting downstream RAS 
signaling (67). Therefore, NF1 loss-of-function determines 
the hyperactivation of NRAS protein and thus, increased 
MAPK and PI3K pathways signaling (65,67,68). NF1 genomic 
alterations are more frequent in melanomas associated with 
Figure 1. Melanocyte malignant transformation. Physiologically, keratinocytes 
induces melanocyte proliferation through the production of MSH hormone and 
its binding with the MC1R. UV-A irradiation induces melanocytes malignant 
transformation through two different mechanisms: The direct transformation 
of normal melanocytes in neoplastic cells through the occurrence of several 
mutations affecting both proto-oncogene and tumor suppressor genes (TP53, 
NF1, PTEN, etc.). The transformation of melanocytes into benign nevi that in 
80% of cases harbor the mutation BRAFV600E. These nevi remain indolent for 
decades also due to immune surveillance; however, UV rays can determine the 
onset of additional genetic mutations, such as TERT and CDKN2A, that lead 
to the malignant transformation of the nevi. MSH, melanocyte-stimulating 
hormone; MC1R, melanocortin 1 receptor; BRAF, B-Raf proto-oncogene; 
CDKN2A, cyclin-dependent kinase inhibitor 2A; TERT, telomerase reverse 
transcriptase; ARID2, AT-rich interaction domain 2; PTEN, phosphatase and 
tensin homolog; NF1, neurofibromin 1; TP53, tumor protein p53; KIT, KIT 
proto-oncogene receptor tyrosine kinase.
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chronically sun-exposed skin and are usually associated 
with a high number of various genomic mutations, including 
co-occurence with BRAF or NRAS mutations (68,69).
The receptor tyrosine kinase KIT is physiologically involved 
in melanoma proliferation and survival through the PI3K/AKT 
and the RAS/RAF/MEK/ERK pathways. Somatic activating 
mutations in this gene have been found in 2-8% of all malignant 
melanomas and are more frequent in acral melanomas and with 
melanoma arising on intermitted sun-exposed skin (70,71).
BRAF, NRAS, NF1 and KIT genomic deregulations are 
considered driver alterations in melanoma development; 
however, a number of other genes are involved in the char-
acterization of invasive and metastatic melanoma genotype. 
TERT promoter mutations confer proliferative advantage to 
melanoma cells and along with heterozygous CDKN2A altera-
tions, have been frequently detected in in situ melanoma (72). 
The CDKN2A gene encodes for p16INK4A, a cyclin-depen-
dent kinase inhibitor. The further bi-allelic inactivation 
of CDKN2A is a subsequent step to the melanoma invasive 
phenotype, rarely observed in precursor lesions (72-74). PTEN 
is a tumor suppressor gene involved in cell cycle progression 
control. PTEN dysregulation is usually detected in vertical 
growth phase melanoma and metastases with a frequency 
of 10-30% of cutaneous melanoma (47,75). Missense and 
frameshift mutations or chromosomal deletions are the most 
frequent alteration detected in PTEN but also epigenetic 
mechanisms and microRNAs post transcriptional regulation 
of PTEN expression have been found (76). The genomic 
alteration involving PTEN are usually mutually exclusive 
with NRAS mutations, but frequently co-occur with BRAF 
gain‑of‑function. This finds its biological rational in the loss 
of PTEN being associated with increased PI3K/AKT pathway 
activation (77,78). Indeed, BRAF mutations and PTEN 
loss-of-function together activate both the MAPK pathway 
and the PI3K pathway, thus being potentially equivalent to 
NRAS-only activation (78,79). In the clinical setting, PTEN 
Table I. Milestone trials for the systemic treatment of advanced, unresectable melanoma.
  Overall response Median progression-free Median overall
Trial name Treatment rate (%) survival (months) survival (months)
BRIM3 (87,121) Dacarbazine 5 1.6 9.7
 versus
 vemurafenib 48 5.3 13.6
coBRIM (93) Vemurafenib 50 7.2 17.4
 versus
 vemurafenib + cobimetinib 69.6 12.3 22.3
BREAK-3 (86) Dacarbazine 7 2.7 Not reported
 versus
 dabrafenib 50 5.1 20
COMBI-d (90) Dabrafenib 51 8.8 18.7
 versus
 dabrafenib + trametinib 67 11  25.1
COMBI-v (89) Vemurafenib 51 7.3 18
 versus
 dabrafenib + trametinib 64 11.4 25.6
CA184-024 (122) Dacarbazine 10.3 3 9.1
 versus
 dacarbazine + ipilimumab 15.2 3 11.2
CheckMate 066 (88) Dacarbazine 13.9 2.2 10.8
 versus
 nivolumab 40 5.1 Not reached
CheckMate 067 (123) Ipilimumab 19 2.9 19.9
 versus
 nivolumab 43.7 6.9 37.6
 versus
 ipilimumab + nivolumab 57.6 11.5 Not reached
KEYNOTE-006 (124) Ipilimumab 11.9 2.8 16
 versus
 pembrolizumab q2w 33.7 5.5 Not reached
 versus
 pembrolizumab q3w 32.9 4.1 Not reached
q2w, every 2 weeks; q3w, every 3 weeks.
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loss-of-function represents one of the mechanism responsible 
for the acquired resistance of BRAF mutant melanoma treated 
with BRAF inhibitors (80).
Even though a conclusive model of recurrent alterations 
leading to metastatic progression has yet to be elucidated, 
β-catenin-mediated WNT signaling activation has been shown 
to be associated with metastatic dissemination, as well as 
melanoma formation (37,81). CTNNB1 (β-catenin) gene muta-
tions are detected in 2-4% of malignant melanomas and act 
through the stabilization of β-catenin and increased transcrip-
tion of TCF/LEF-responsive target genes (82).
4. Principles of medical treatment
The majority of patients with newly-diagnosed melanoma 
have early-stage disease. For these patients, surgical exci-
sion represents the treatment of choice and is curative in 
the majority of cases (83). However, some patients will later 
relapse with disseminated disease, while approximately 10% 
of melanoma cases are diagnosed at an advanced stage, and 
are unresectable or already metastatic. Among stage IV 
tumors, approximately one-third have visceral and brain 
involvement at diagnosis, with a severe prognosis and lower 
probability to have a sustained response to treatment (84). 
For patients facing advanced-stage disease, melanoma treat-
ment has been revolutionized since 2011, with the approval 
of several therapeutic agents. These agents include RAF 
and MEK kinase inhibitors, as well as immune checkpoint 
inhibitors [anti-cytotoxic T-lymphocyte-associated antigen 4 
antibodies (anti-CTLA4) and anti-programmed cell death 
protein 1 antibody (anti-PD1)]. Indeed, in the advanced-stage 
setting, anti-PD1 and anti-CTLA4 antibodies (such as 
nivolumab, pembrolizumab and ipilimumab), as well as selec-
tive BRAF inhibitors (vemurafenib and dabrafenib) alone 
and/or in combination with MEK inhibitors (cobimetinib and 
trametinib) have shown promising results in clinical trials 
(Table I) (85-93). Currently, only the presence of BRAFV600E 
mutation is evaluated in the clinical setting, as it is essential 
to drive the appropriate treatment strategy. Other driver muta-
tions, such as NRAS, NF1, CKIT, CDKN2A and PTEN, have 
not yet been included in standard clinical practice. However, 
the identification of these genomic alterations can identify 
patients who may benefit of experimental approach in clinical 
trials.
Immunotherapy and kinase inhibitors are nowadays the 
backbone of systemic therapy, while chemotherapy is consid-
ered a second-line, or even further, treatment option (94-96) 
(Fig. 2). Anti-PD1 antibodies and, with lower magnitude 
anti-CTLA4 therapeutic agents, offer lower response rates, but 
potentially long durable responses (85,91,92). In BRAFV600E 
melanoma, there has been a reasonable approach to the use of 
BRAF inhibitors with MEK inhibitors. The combination has 
led to high response rates (70%) and a rapid response induc-
tion and symptom control, with a progression-free survival of 
approximately 12 months (89,90,93). To date, however, there are 
no available data from prospective trials on the optimal choice 
for frontline treatment and treatment sequence, at least to the 
best of our knowledge. Nivolumab and pembrolizumab have 
shown to be effective on BRAF mutant melanoma after BRAF 
inhibitor resistance has risen, but there are no similar data 
for ipilimumab or for BRAF-inhibitor therapy in those with 
primary or secondary resistance to anti-PD-1 therapy (97-99). 
Currently, the combination of two different immune check-
point inhibitors or the combination anti-PD1/anti-CTLA4 
with targeted therapy must be considered an experimental 
approach in clinical trials. Each strategy has a clear benefit 
and basic research has demonstrated significant synergistic 
effects that need to be weighted with the potential increase in 
toxicity (100,101).
The inclusion of patient characteristics [biochemical param-
eters of melanoma kinetics, such us lactate dehydrogenase 
(LDH)] and expected toxicity profile, as well as comorbidities 
and patient personal preferences are central elements to be 
taken into account for frontline treatment strategy definition. 
In this rapidly evolving landscape, it is of great importance the 
participation of patients in randomized clinical trials.
Figure 2. Medical treatment of melanoma. The therapeutic approaches for the 
melanoma treatment are based on serine/threonine protein kinase inhibitors 
and the news immune checkpoint inhibitors. Dabrafenib and vemurafenib 
are selective RAF inhibitors; cobimetinib and trametinib are selective MEK 
inhibitors; ipilimumab is a monoclonal antibody IgG1k anti-CTLA-4, while 
nivolumab and pembrolizumab are PD-1 monoclonal antibodies IgG4 and 
IgG4k anti-PD-1, respectively. All these monoclonal antibodies enhance the 
efficacy of the immune system that is able to recognize and eradicate tumor 
cells. GF, growth factor; GFR, growth factor receptor; IRS1, insulin receptor 
substrate 1; SOS, son of sevenless; Shc, SHC adaptor protein; Grb2, growth 
factor receptor bound protein 2; RAS: RAS proto-oncogene GTPase; BRAF, 
B-Raf proto-oncogene; C-RAF: RAF-1 proto-oncogene; MAPK, mitogen-acti-
vated protein kinase; ERK, mitogen-activated protein kinase 1; MHC, major 
histocompatibility complex; TCR, T-cell receptor; PD-1, programmed cell 
death protein 1; PD-L1, programmed death-ligand 1; APC, antigen-presenting 
cell; B7-1/2, CD80/CD86; CTLA-4, cytotoxic T-lymphocyte antigen 4.
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5. Predictive biomarkers in melanoma
The identification of biomarkers that can predict patient 
benefits towards specific treatment strategies is a central goal 
of cancer research. BRAF mutations, particular BRAFV600E, 
is a typical predictive marker of response to RAF inhibitors. 
However, these patients almost invariably develop disease 
progression after a variable period of time and some 
patients can display primary resistance to BRAF (+/- MEK) 
inhibitors. Several studies have described the central role of 
acquired genetic mutations affecting the Ras/Raf/MEK/ERK 
and PI3K/PTEN/Akt/mTOR signaling pathways in inducing 
resistance to both chemotherapy and targeted therapy in 
melanoma and other tumor types (102-104). In particular, the 
mechanisms responsible for BRAF (+/- MEK) inhibitor resis-
tance can be divided into genomic (NRAS/KRAS mutation 
20%, BRAF splice variants 16%, BRAF amplification 13%, 
MEK1/2 mutation 7%, bypass track mutations 11%), immu-
nologic (epigenetic and transcriptomic changes of molecules 
involved in antigen presenting mechanisms) and a combina-
tion of both (105,106).
Currently, the detection of the mechanisms responsible for 
BRAF and MEK inhibitor resistance is not part of standard 
clinical practice; however, the development of non-invasive 
techniques for tumor mutational status assessment may lead 
to more rapid changes in this setting (107). The technique 
termed ‘liquid biopsy’ enables the detection of tumor-derived 
circulating cell-free DNA (ctDNA) in the plasma and is 
emerging as a promising blood-based biomarker for moni-
toring the melanoma disease status. Several studies have 
indicated that BRAFV600E detection through ctDNA prior to 
the commencement of treatment is predictive of the response 
to BRAF kinase inhibitors, and that high basal ctDNA levels 
are associated with a lower response rate and progression-free 
survival (107-109). Moreover, ctDNA is an indicator of tumor 
burden and tumor dynamics, and it has been demonstrated 
that an increase in ctDNA levels during treatment is indica-
tive of disease progression and acquired resistance (107,109). 
Notably, ctDNA can be used also for the detection of muta-
tions responsible for resistance to BRAF targeted therapies 
and in the future, this can be used to guide subsequent treat-
ment strategies (107,109).
Immune checkpoint inhibitors are associated with a low 
overall response rate (ORR). This has driven considerable 
research efforts in the identification of biomarkers able to 
predict which patients will more likely benefit from these 
treatments. At this point, PD-L1 immunohistochemistry on 
tumor specimens is not a candidate marker for PD-1 inhib-
itor treatment response, due to the extremely heterogeneous 
results obtained from clinical trials (88,99). Several other 
predictive biomarkers are currently under investigation. 
The specific components of melanoma microenvironment 
and in particular the CD8+ T cell activation, through IFN-γ 
gene expression signature, has been associated with immu-
notherapy response (110,111). Moreover, several studies 
have demonstrated the mechanisms through which specific 
genomic alterations can drive immune checkpoint resistance 
through the alteration of antigen-presenting mechanisms 
and IFN-γ production (112-114). Recently, in humans, it has 
been demonstrated that specific gut microbiota compositions 
can drive differential responses to immune checkpoint 
inhibitors (115‑117). This is not only a new intriguing field 
of research for immunotherapy biomarkers, but it also paves 
the way for the potential modulation of human gut micro-
biota composition to improve the immunotherapy response. 
As regards the identification of complex biological interac-
tions among different pathways and their interplay with 
the immune system, bioinformatics has yielded promising 
results. In this context, computational models can simulate 
biochemical, metabolic and immune mediated interac-
tions and characterize how they are potentially involved in 
melanoma development (118,119). Overall, computational 
approaches may potentially lead to the identification of novel 
therapeutic targets and may accelerate the drug discovery 
process (120).
6. Conclusions
Marked improvements in melanoma treatment have been 
achieved over the past decade. The tireless efforts of researchers 
have shed light on essential mechanisms involved in melanoma 
biology, paving the way for targeted treatment and immuno-
therapy. However, melanoma remains a lethal type of cancer, 
particularly when diagnosed at an advanced stage. Further 
elucidation of melanoma biology and evolution also in pres-
ence of treatment-selective pressure represent a central goal of 
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